Patents by Inventor Deborah A. Moore

Deborah A. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11866476
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Grant
    Filed: December 28, 2022
    Date of Patent: January 9, 2024
    Assignee: Xilio Development, Inc.
    Inventors: Margaret Karow, Deborah Moore Lai, Dheeraj Tomar, Parker Johnson, Raphael Rozenfeld, Ronan O'Hagan, Huawei Qiu
  • Patent number: 11827686
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: November 28, 2023
    Assignee: Xilio Development, Inc.
    Inventors: Margaret Karow, Deborah Moore Lai, Dheeraj Singh Tomar, Parker Johnson, Raphael Rozenfeld, Ronan O'Hagan, Huawei Qiu
  • Patent number: 11827685
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: November 28, 2023
    Assignee: Xilio Development, Inc.
    Inventors: Margaret Karow, Deborah Moore Lai, Dheeraj Singh Tomar, Parker Johnson, Raphael Rozenfeld, Ronan O'Hagan, Huawei Qiu
  • Patent number: 11718655
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: August 8, 2023
    Assignee: XILIO DEVELOPMENT, INC.
    Inventors: Margaret Karow, Deborah Moore Lai, Dheeraj Tomar, Parker Johnson, Raphael Rozenfeld, Ronan O'Hagan, Huawei Qiu
  • Publication number: 20230235006
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Application
    Filed: December 28, 2022
    Publication date: July 27, 2023
    Applicant: Xilio Development, Inc.
    Inventors: Margaret KAROW, Deborah Moore LAI, Dheeraj TOMAR, Parker JOHNSON, Raphael ROZENFELD, Ronan O'HAGAN, Huawei QIU
  • Publication number: 20230135462
    Abstract: Cyanoacrylate compositions are provided, which when cured provide improved hot strength performance without compromising thermal resistance performance.
    Type: Application
    Filed: December 22, 2022
    Publication date: May 4, 2023
    Inventors: Tammy Gernon, Michael Jordan, Susan Reilly, Martin Smyth, Deborah Moore, Patricia Hedderman, Aine Mooney
  • Publication number: 20230034325
    Abstract: A container for curable cyanoacrylate composition comprising: a reservoir for holding curable cyanoacrylate composition, the reservoir having an outlet through which the curable cyanoacrylate composition can be dispensed; the reservoir being defined by walls of plastics material, the plastics material being formed by a polymer material that is transmissive to both visible light and UV light; and a UV blocking agent dispersed in the plastics material the UV blocking agent comprising at least one benzotriazole; the walls of the container being transmissive to visible light and non-transmissive to UV light. Curable cyanoacrylate compositions held within such a container are thus storage stable in ambient conditions and yet the curable cyanoacrylate compositions can be seen through the walls of the container. A pack comprising the container and a curable cyanoacrylate composition is also described.
    Type: Application
    Filed: June 20, 2022
    Publication date: February 2, 2023
    Inventors: Aine Mooney, Tammy Gernon, Susan Reilly, Martin Smyth, Deborah Moore, Michael Jordan, Patricia Hedderman, Bryan Brady, Lydie Coulombel, Henry Loughrey
  • Publication number: 20230030037
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Application
    Filed: June 4, 2021
    Publication date: February 2, 2023
    Applicants: Xilio Development, Inc., Xilio Development, Inc.
    Inventors: Margaret KAROW, Deborah Moore LAI, Dheeraj Singh TOMAR, Parker JOHNSON, Raphael ROZENFELD, Ronan O'HAGAN, Huawei QIU
  • Publication number: 20230028959
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Application
    Filed: June 4, 2021
    Publication date: January 26, 2023
    Inventors: Margaret KAROW, Deborah Moore LAI, Dheeraj Singh TOMAR, Parker JOHNSON, Raphael ROZENFELD, Ronan O'HAGAN, Huawei QIU
  • Publication number: 20220306716
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Application
    Filed: April 8, 2022
    Publication date: September 29, 2022
    Applicant: Xilio Development, Inc.
    Inventors: Margaret KAROW, Deborah Moore LAI, Dheeraj TOMAR, Parker JOHNSON, Raphael ROZENFELD, Ronan O'HAGAN, Huawei QIU
  • Publication number: 20220002370
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Application
    Filed: September 27, 2019
    Publication date: January 6, 2022
    Inventors: Margaret KAROW, Deborah Moore LAI, Dheeraj TOMAR, Parker JOHNSON, Raphael ROZENFELD, Ronan O'HAGAN, Huawei QIU
  • Publication number: 20210395571
    Abstract: Two-part cyanoacrylate/cationically curable adhesive systems, are provided.
    Type: Application
    Filed: September 3, 2021
    Publication date: December 23, 2021
    Inventors: Aine Mooney, Susan Reilly, Deborah Moore
  • Patent number: 11053294
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e g masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: July 6, 2021
    Assignee: Xilio Development, Inc.
    Inventors: Margaret Karow, Deborah Moore Lai, Dheeraj Singh Tomar, Parker Johnson, Raphael Rozenfeld, Ronan O'Hagan, Huawei Qiu
  • Publication number: 20210002343
    Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e g masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
    Type: Application
    Filed: August 25, 2020
    Publication date: January 7, 2021
    Inventors: Margaret KAROW, Deborah Moore LAI, Dheeraj Singh TOMAR, Parker JOHNSON, Raphael ROZENFELD, Ronan O'HAGAN, Huawei QIU
  • Publication number: 20160128391
    Abstract: A side opening garment having a side opening for use in allowing the user to put on the garment using only one hand. The garment comprises a shirt having an upper end, an open lower end, and a pair of sleeves. A side of the body includes an opening extending from the lower end of the garment upward toward the sleeve, and along the underside of the sleeve. The opening can be positioned on the left side or right side of the shirt, depending upon the embodiment. A first edge of the opening and a second edge of the opening include fasteners thereon that can be removably secured to seal the opening. In this way, the garment allows a user to put on one side of the shirt in the conventional manner, while adorning the opposing side of the shirt by sealing the opening.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 12, 2016
    Inventor: Deborah Moore
  • Patent number: 9120957
    Abstract: Cyanoacrylate-containing compositions that include, in addition to the cyanoacrylate component, a hydrogenated anhydride and optionally a benzonitrile, are provided. Cured products of the inventive cyanoacrylate compositions demonstrate improved heat resistance without compromising fixture time, stability or color.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: September 1, 2015
    Assignee: Henkel IP & Holding GmbH
    Inventors: Patricia A. Hedderman, Emer Ward, William Hally, Deborah A. Moore, Cormac Duffy, Marisa Phelan
  • Patent number: 8981027
    Abstract: Two part cyanoacrylate/cationically curable adhesive systems are provided.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 17, 2015
    Assignee: Henkel IP & Holding GmbH
    Inventors: Emer Ward, Susan Reilly, Patricia A. Hedderman, Rachel Hersee, Deborah A. Moore
  • Patent number: 8933168
    Abstract: There is provided a cyanoacrylate composition comprising: a cyanoacrylate; and a 2-substituted benzothiazole or a derivative thereof wherein the 2-substituent is an alkyl, an alkene, an alkylbenzyl, an alkylamino, an alkoxy, an alkylhydroxy, an ether, a sulfenamide, a thioalkyl or a thioalkoxy group, with the proviso that an amide portion of the sulfenamide does not have a tert butylamino or a morpholine group.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: January 13, 2015
    Assignee: Henkel IP & Holding GmbH
    Inventors: William Hally, Emer Ward, Patricia A. Hedderman, Deborah A. Moore, Dermot F. Heatley
  • Publication number: 20140275419
    Abstract: Two part cyanoacrylate/cationically curable adhesive systems are provided.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: Henkel Ireland Limited
    Inventors: Emer Ward, Susan Reilly, Patricia A. Hedderman, Rachel Hersee, Deborah A. Moore
  • Publication number: 20140124137
    Abstract: Cyanoacrylate-containing compositions that include, in addition to the cyanoacrylate component, a hydrogenated anhydride and optionally a benzonitrile, are provided. Cured products of the inventive cyanoacrylate compositions demonstrate improved heat resistance without compromising fixture time, stability or color.
    Type: Application
    Filed: January 14, 2014
    Publication date: May 8, 2014
    Applicant: Henkel lP & Holding GmbH
    Inventors: Patricia A. Hedderman, Emer Ward, William Hally, Deborah A. Moore, Cormac Duffy, Marisa Phelan